Literature DB >> 20600943

Enhanced periplasmic expression of high affinity humanized scFv against Hepatitis B surface antigen by codon optimization.

Ashutosh Tiwari1, Anurag Sankhyan, Navin Khanna, Subrata Sinha.   

Abstract

Production of properly folded, functional recombinant antibodies in a prokaryotic system is governed by multiple factors like codon usage, plasmid copy number, upstream elements such as leader sequence, mRNA stability and presence of tightly controlled promoters. Here we present a strategy for enhanced production of the functional scFv in Escherichia coli by codon optimization. We have previously reported the generation of humanized scFv form of a potentially neutralizing mouse monoclonal antibody (5S) to the Hepatitis B surface antigen. However, the expression level of 5S-scFv in E. coli was fairly low which was possibly due to the presence of rare codons. In the native 5S-scFv gene, almost 58% of codons showed poor codon bias with varying degrees of rare occurrence in the E. coli genes. We therefore designed a synthetic gene encoding the 5S-scFv protein by using E. coli preferred codon usage. The codon-optimized scFv gene was further cloned into a T7 expression system with a C-terminus His-tag and expressed as a soluble protein mainly in the periplasm. The scFv was both purified by IMAC and detected on Western blot with this His-tag. Using the codon optimization strategy, we were able to achieve a more than 100-fold increased periplasmic expression of soluble scFv. Further, the purified scFv was stable and retained its antigen-binding affinity and epitope specificity. Interestingly, based on secondary structure prediction, we observed that the mRNA secondary structure, including that of the 5'-end, may not have a significant role in the increased expression of this optimized gene.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600943     DOI: 10.1016/j.pep.2010.06.006

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  6 in total

1.  Electrostatic engineering of the interface between heavy and light chains promotes antibody Fab fragment production.

Authors:  Yuki Ohmuro-Matsuyama; Keita Mori; Hirotsugu Hamada; Hiroshi Ueda; Hideki Yamaji
Journal:  Cytotechnology       Date:  2016-02-08       Impact factor: 2.058

Review 2.  Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.

Authors:  Chung-Jr Huang; Henry Lin; Xiaoming Yang
Journal:  J Ind Microbiol Biotechnol       Date:  2012-01-18       Impact factor: 3.346

3.  Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein.

Authors:  Hajarossadat Ghaderi; Zahra Noormohammadi; Mahdi Habibi-Anbouhi; Fatemeh Kazemi-Lomedasht; Mahdi Behdani
Journal:  Iran J Basic Med Sci       Date:  2021-12       Impact factor: 2.699

4.  Expression and Functional Properties of an Anti-Triazophos High-Affinity Single-Chain Variable Fragment Antibody with Specific Lambda Light Chain.

Authors:  Rui Liu; Xiao Liang; Dandan Xiang; Yirong Guo; Yihua Liu; Guonian Zhu
Journal:  Int J Mol Sci       Date:  2016-06-07       Impact factor: 5.923

5.  Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals.

Authors:  Anurag Sankhyan; Chandresh Sharma; Durgashree Dutta; Tarang Sharma; Kunzang Chosdol; Takaji Wakita; Koichi Watashi; Amit Awasthi; Subrat K Acharya; Navin Khanna; Ashutosh Tiwari; Subrata Sinha
Journal:  Sci Rep       Date:  2016-02-18       Impact factor: 4.379

6.  Construction and Periplasmic Expression of the Anti-EGFRvIII ScFv Antibody Gene in Escherichia coli.

Authors:  Kartika Sari Dewi; Debbie Sofie Retnoningrum; Catur Riani; Asrul Muhamad Fuad
Journal:  Sci Pharm       Date:  2016-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.